Premium
A L i T at 1.5 variant surface glycoprotein‐derived peptide with diagnostic potential for T rypanosoma brucei gambiense
Author(s) -
Nieuwenhove Liesbeth,
Büscher Philippe,
Balharbi Fatima,
Humbert Michael,
Guisez Yves,
Lejon Veerle
Publication year - 2013
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1111/tmi.12058
Subject(s) - peptide , biotinylation , glycoprotein , biology , epitope , microbiology and biotechnology , monoclonal antibody , peptide sequence , biochemistry , antibody , immunology , gene
Objective To evaluate the accuracy of a peptide, corresponding to the variant surface glycoprotein ( VSG ) LiTat 1.5 amino acid ( AA ) sequence 268–281 and identified through alignment of monoclonal antibody selected mimotopes, for diagnosis of T rypanosoma brucei gambiense sleeping sickness. Methods A synthetic biotinylated peptide (peptide 1.5/268–281), native VSG LiTat 1.3 and VSG LiTat 1.5 were tested in an indirect ELISA with 102 sera from patients with HAT and 102 endemic HAT ‐negative controls. Results The area under the curve ( AUC ) of peptide 1.5/268–281 was 0.954 (95% confidence interval 0.918–0.980), indicating diagnostic potential. The areas under the curve of VSG LiTat 1.3 and LiTat 1.5 were 1.000 (0.982–1.000) and 0.997 (0.973–1.000), respectively, and significantly higher than the AUC of peptide 1.5/268–281. On a model of VSG LiTat 1.5, peptide 1.5/268–281 was mapped near the top of the VSG . Conclusions A biotinylated peptide corresponding to AA 268–281 of VSG LiTat 1.5 may replace the native VSG in serodiagnostic tests, but the diagnostic accuracy is lower than for the full‐length native VSG LiTat 1.3 and VSG LiTat 1.5.